Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 56, Issue 14, Pages 5843-5859Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm400567s
Keywords
-
Categories
Funding
- China Postdoctoral Science Foundation [2012M251651]
- Ph.D. Programs Foundation of the Ministry of Education of China [20120171120045]
- Guangdong Engineering Research Center of Chiral Drugs
- Natural Science Foundation of China [20972198]
Ask authors/readers for more resources
A series of multitarget-directed resveratrol derivatives was designed and synthesized for the treatment of Alzheimer's disease (AD). In vitro studies indicated that most of the target compounds exhibit significant inhibition of self-induced beta-amyloid (A beta) aggregation and Cu(II)-induced A beta(1-42) aggregation and acted as potential antioxidants and biometal chelators. In particular, compounds 5d and 10d are potential lead compounds for AD therapy (5d, IC50 = 7.56 mu M and 10d, IC50 = 6.51 mu M for self-induced A beta aggregation; the oxygen radical absorbance capacity assay using fluorescein (ORAC-FL) values are 4.72 and 4.70, respectively). Moreover, these compounds are capable of disassembling the highly structured A beta fibrils generated by self- and Cu(II)-induced A beta aggregation. Furthermore, 5d crossed the blood-brain barrier (BBB) in vitro and did not exhibit any acute toxicity in mice at doses of up to 2000 mg/kg. Taken together, the data indicate that 5d is a very promising lead compound for AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available